Current Practices in Dyslipidemia Management Among  Diabetologists in India: a Cross-Sectional Survey

Kunal Khobragade; Pratibha Karande; Kunal Khobragade; Pratibha Karande

doi:10.61096/ijamscr.v13.iss3.2025.507-516

Issue

Vol. 13 No. 3 (2025): 2025 Volume -13 - Issue 3

Date Log

Published

August 27, 2025

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Current Practices in Dyslipidemia Management Among Diabetologists in India: a Cross-Sectional Survey

https://doi.org/10.61096/ijamscr.v13.iss3.2025.507-516

Kunal Khobragade

MBBS MD VP and Head Medical Affairs, Mankind Pharmaceuticals Ltd, Seawood Railway Station, Nerul Node, Navi Mumbai- 400706

Pratibha Karande

MBBS AFIH AGM, Medical Affairs, Mankind Pharmaceuticals Ltd, Seawood Railway Station, Nerul Node, Navi Mumbai- 400706

Corresponding Author(s) : Pratibha Karande

pratibha.karande@mankindpharma.com

International Journal of Allied Medical Sciences and Clinical Research, Vol. 13 No. 3 (2025): 2025 Volume -13 - Issue 3
Article Published : August 27, 2025

Abstract

Dyslipidemia remains a major contributor to cardiovascular risk among individuals with diabetes, yet real-world insights into its management are limited. This cross-sectional, questionnaire-based survey was conducted among 337 diabetologists across India between August and October 2024 to evaluate clinical practices in dyslipidemia management. The validated 20-item questionnaire explored four key domains: patient profile, diagnostic parameters, treatment preferences, and monitoring practices. Findings revealed a high prevalence of dyslipidemia and suboptimal achievement of lipid targets. Statins remained the cornerstone of therapy; however, variability was observed in risk stratification approaches, treatment goals, and monitoring frequency. Despite awareness of guideline recommendations, delayed intervention and treatment gaps persisted. The survey highlights the need for more consistent adherence to evidence-based guidelines and supports targeted educational interventions to optimize lipid management and reduce cardiovascular risk in the diabetic population in India

Keywords

Dyslipidemia Diabetes Mellitus Lipid Management Statin Therapy Real-World Survey

Kunal Khobragade, Pratibha Karande. Current Practices in Dyslipidemia Management Among Diabetologists in India: a Cross-Sectional Survey. Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2025 Aug. 27 [cited 2026 Apr. 15];13(3):507-16. Available from: https://ijamscr.com/ijamscr/article/view/1662

Download Citation

References

Saboo, B.D., Agarwal, S., Makkar, B., Chawla, R., Ghosh, S., Viswanathan, V., Gupta, S., Ch. Vasanth Kumar, Maheshwari, A., L. Sreenivasamurthy, Sahay, R., Reddy, S.G., Jaggi, S., Jugal Kishor Sharma, Vijay Panikar, Moses, A., Bhattacharjee, B., Pratap Jethwani, Bhandari, S. and Sawhney, J.P.S. RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus. International Journal of Diabetes in Developing Countries, 42(1), (2022), pp.3–28. doi:https://doi.org/10.1007/s13410-022-01063-6.
Bhattacharjee, J., Prakash Gogoi, P., & Baruah, K. K. (n.d.). PREVALENCE OF DYSLIPIDEMIA AMONG TYPE 2 DIABETIC PATIENTS IN SOUTHERN ASSAM, INDIA:A CROSS-SECTIONAL STUDY. International Journal of Medicine and Public Health, 15. https://doi.org/10.70034/ijmedph.2025.1.268
Schofield, J.D., Liu, Y., Rao-Balakrishna, P., Malik, R.A. and Soran, H. Diabetes Dyslipidemia. Diabetes Therapy, [online] 7(2), (2016), pp.203–219. doi:https://doi.org/10.1007/s13300-016-0167-x.
Abbasi, A., Corpeleijn, E., Gansevoort, R.T., Gans, R.O.B., Hillege, H.L., Stolk, R.P., Navis, G., Bakker, S.J.L. and Dullaart, R.P.F. Role of HDL Cholesterol and Estimates of HDL Particle Composition in Future Development of Type 2 Diabetes in the General Population: The PREVEND Study. The Journal of Clinical Endocrinology & Metabolism, 98(8), (2013), pp.E1352–E1359. doi:https://doi.org/10.1210/jc.2013-1680.
Feingold, K. R. (2000). Dyslipidemia in Patients with Diabetes.
Section 10: Cardiovascular Disease and Risk Management. Clinical Diabetes. (2025), doi:https://doi.org/10.2337/cd25-a010.
Abhyankar, M., Iyengar, S., Narasingan, S., Gandhi, P., Jaipuriar, N., Mahilmaran, A., Patil, S. and Revankar, S. Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study. Journal of Family Medicine and Primary Care, 9(8), (2020), p.4156. doi:https://doi.org/10.4103/jfmpc.jfmpc_546_20.
Tandon, N., Fatmi, Z., Kondal, D., Shivashankar, R., Iqbal, R., Khan, A., Mohan, D., Pradeepa, R., Gupta, R., Ali, M., Ajay, V., Mohan, V., Kadir, M., Narayan, K.V. and Prabhakaran, D. Prevalence of dyslipidaemia and factors associated with dyslipidaemia among South Asian adults: The Center for Cardiometabolic Risk Reduction in South Asia Cohort Study. The National Medical Journal of India, 33(3), (2020), p.137. doi:https://doi.org/10.4103/0970-258x.314005.
SantoshY Revankar, Kalra, S., Kumar, S., Pandit, K., Anantharaman, R., Dhingra, A., I Periyandavar, Chawla, M., Mohan Magdum, Desai, P., Deb, P., Rajasekaran, S., Nair, R., Shaikh, S., Subodh Banzal, Kota, S., Shah, T. and Gupta, A. Pragmatic and early usage of statin in patients with diabetes for prevention of atherosclerotic cardiovascular disease: Survey-based opinions of indian health-care practitioners. Chronicle of Diabetes Research and Practice, [online] 2(1), (2023) pp.4–4. doi:https://doi.org/10.4103/cdrp.cdrp_cdrp_18_22.
Rikhi, R. and Shapiro, M.D. Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention. Current Cardiology Reports. (2024), doi:https://doi.org/10.1007/s11886-024-02141-3.
Puri, R., Mehta, V., Duell, P.B., Wangnoo, S., Rastogi, A., Mohan, V., Zargar, A.H., Kalra, S., Sahoo, A.K., Iyengar, S., Yusuf, J., Mukhopadhyay, S., Singla, M.K., Shaikh, A., Kohli, S., Mathur, S., Jain, S., Narasingan, S., Gupta, V. and Agarwala, R. Management of diabetic dyslipidemia in Indians: Expert consensus statement from the lipid association of India. Journal of Clinical Lipidology. (2022) [online] doi:https://doi.org/10.1016/j.jacl.2022.11.002.
Vergès, B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia, [online] 58(5), (2015), pp.886–899. doi:https://doi.org/10.1007/s00125-015-3525-8.
Bekele, S., Yohannes, T. and Abdurehman Eshete Mohammed. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region. Diabetes, metabolic syndrome and obesity, Volume 10, (2017), pp.265–271. doi:https://doi.org/10.2147/dmso.s135064.
Ikeda, I., Igarashi, R., Fujihara, K., Takeda, Y., Ferreira, E. d'Ávila, Mon, K.L., Kodama, S., Mori, Y., Kadowaki, T., Honda, R., Arase, Y. and Sone, H. Cross-sectional and Longitudinal Associations Between Family History of Type 2 Diabetes Mellitus, Hypertension, and Dyslipidemia and Their Prevalence and Incidence: Toranomon Hospital Health Management Center Study (TOPICS24). Mayo Clinic Proceedings. (2025), [online] doi:https://doi.org/10.1016/j.mayocp.2024.10.020.
Grundy, S.M., Stone, N.J., Bailey, A.L., Beam, C., Birtcher, K.K., Blumenthal, R.S., Braun, L.T., de Ferranti, S., Faiella-Tommasino, J., Forman, D.E., Goldberg, R., Heidenreich, P.A., Hlatky, M.A., Jones, D.W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C.E., Orringer, C.E., Peralta, C.A. and Saseen, J.J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25). (2019), doi:https://doi.org/10.1161/cir.0000000000000624.
Sniderman, A.D.. ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease. Clinical Chemistry. (2021), doi:https://doi.org/10.1093/clinchem/hvab140.
Tran, C., Vo, V., Taylor, P., Koehn, D.A., Virani, S.S. and Dixon, D.L. Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center. Journal of clinical lipidology, 16(4), (2022), pp.491–497. doi:https://doi.org/10.1016/j.jacl.2022.05.003.
Chait, A., Eckel, R.H., Vráblík, M. and Zambón, A. Lipid-lowering in diabetes: An update. Atherosclerosis, 394, (2023), pp.117313–117313. doi:https://doi.org/10.1016/j.atherosclerosis.2023.117313.
O’Toole, T., Kelsey, M.D., Shah, N.P., McGarrah, R.W. and Pagidipati, N.J.. Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs. Current Cardiology Reports, 24(10), (2022), pp.1397–1406. doi:https://doi.org/10.1007/s11886-022-01760-y.
Jain, M., Sawant, R., Panchal, H., S, A., Jena, A., Gupta, R., Kumar, K., Jambunathan, R., Modi, S., Mullasari, A., Sinha, N., Shetty, K. and Kawatra, P. Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- A retrospective real-world study LDL-C control in ACS. International Journal of Cardiology Cardiovascular Risk and Prevention, [online] 19, (2023), p.200210. doi:https://doi.org/10.1016/j.ijcrp.2023.200210.
Laakso, M. and Lilian Fernandes Silva. Statins and risk of type 2 diabetes: Mechanism and clinical implications. Frontiers in Endocrinology, (2023), [online] 14(1239335). doi:https://doi.org/10.3389/fendo.2023.1239335.
Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B.G., Bruckert, E., De Backer, G., Krauss, R.M., Laufs, U., Santos, R.D., Hegele, R.A., Hovingh, G.K., Leiter, L.A., Mach, F. and März, W. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36(17), (2015), pp.1012–1022. doi:https://doi.org/10.1093/eurheartj/ehv043.
Martirossian, A.N. and Goldberg, A.C. Management of patients with statin intolerance. Best Practice & Research Clinical Endocrinology & Metabolism, 37(3), (2022), p.101714. doi:https://doi.org/10.1016/j.beem.2022.101714.

References

Saboo, B.D., Agarwal, S., Makkar, B., Chawla, R., Ghosh, S., Viswanathan, V., Gupta, S., Ch. Vasanth Kumar, Maheshwari, A., L. Sreenivasamurthy, Sahay, R., Reddy, S.G., Jaggi, S., Jugal Kishor Sharma, Vijay Panikar, Moses, A., Bhattacharjee, B., Pratap Jethwani, Bhandari, S. and Sawhney, J.P.S. RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus. International Journal of Diabetes in Developing Countries, 42(1), (2022), pp.3–28. doi:https://doi.org/10.1007/s13410-022-01063-6.

Bhattacharjee, J., Prakash Gogoi, P., & Baruah, K. K. (n.d.). PREVALENCE OF DYSLIPIDEMIA AMONG TYPE 2 DIABETIC PATIENTS IN SOUTHERN ASSAM, INDIA:A CROSS-SECTIONAL STUDY. International Journal of Medicine and Public Health, 15. https://doi.org/10.70034/ijmedph.2025.1.268

Schofield, J.D., Liu, Y., Rao-Balakrishna, P., Malik, R.A. and Soran, H. Diabetes Dyslipidemia. Diabetes Therapy, [online] 7(2), (2016), pp.203–219. doi:https://doi.org/10.1007/s13300-016-0167-x.

Abbasi, A., Corpeleijn, E., Gansevoort, R.T., Gans, R.O.B., Hillege, H.L., Stolk, R.P., Navis, G., Bakker, S.J.L. and Dullaart, R.P.F. Role of HDL Cholesterol and Estimates of HDL Particle Composition in Future Development of Type 2 Diabetes in the General Population: The PREVEND Study. The Journal of Clinical Endocrinology & Metabolism, 98(8), (2013), pp.E1352–E1359. doi:https://doi.org/10.1210/jc.2013-1680.

Feingold, K. R. (2000). Dyslipidemia in Patients with Diabetes.

Section 10: Cardiovascular Disease and Risk Management. Clinical Diabetes. (2025), doi:https://doi.org/10.2337/cd25-a010.

Abhyankar, M., Iyengar, S., Narasingan, S., Gandhi, P., Jaipuriar, N., Mahilmaran, A., Patil, S. and Revankar, S. Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study. Journal of Family Medicine and Primary Care, 9(8), (2020), p.4156. doi:https://doi.org/10.4103/jfmpc.jfmpc_546_20.

Tandon, N., Fatmi, Z., Kondal, D., Shivashankar, R., Iqbal, R., Khan, A., Mohan, D., Pradeepa, R., Gupta, R., Ali, M., Ajay, V., Mohan, V., Kadir, M., Narayan, K.V. and Prabhakaran, D. Prevalence of dyslipidaemia and factors associated with dyslipidaemia among South Asian adults: The Center for Cardiometabolic Risk Reduction in South Asia Cohort Study. The National Medical Journal of India, 33(3), (2020), p.137. doi:https://doi.org/10.4103/0970-258x.314005.

SantoshY Revankar, Kalra, S., Kumar, S., Pandit, K., Anantharaman, R., Dhingra, A., I Periyandavar, Chawla, M., Mohan Magdum, Desai, P., Deb, P., Rajasekaran, S., Nair, R., Shaikh, S., Subodh Banzal, Kota, S., Shah, T. and Gupta, A. Pragmatic and early usage of statin in patients with diabetes for prevention of atherosclerotic cardiovascular disease: Survey-based opinions of indian health-care practitioners. Chronicle of Diabetes Research and Practice, [online] 2(1), (2023) pp.4–4. doi:https://doi.org/10.4103/cdrp.cdrp_cdrp_18_22.

Rikhi, R. and Shapiro, M.D. Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention. Current Cardiology Reports. (2024), doi:https://doi.org/10.1007/s11886-024-02141-3.

Puri, R., Mehta, V., Duell, P.B., Wangnoo, S., Rastogi, A., Mohan, V., Zargar, A.H., Kalra, S., Sahoo, A.K., Iyengar, S., Yusuf, J., Mukhopadhyay, S., Singla, M.K., Shaikh, A., Kohli, S., Mathur, S., Jain, S., Narasingan, S., Gupta, V. and Agarwala, R. Management of diabetic dyslipidemia in Indians: Expert consensus statement from the lipid association of India. Journal of Clinical Lipidology. (2022) [online] doi:https://doi.org/10.1016/j.jacl.2022.11.002.

Vergès, B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia, [online] 58(5), (2015), pp.886–899. doi:https://doi.org/10.1007/s00125-015-3525-8.

Bekele, S., Yohannes, T. and Abdurehman Eshete Mohammed. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region. Diabetes, metabolic syndrome and obesity, Volume 10, (2017), pp.265–271. doi:https://doi.org/10.2147/dmso.s135064.

Ikeda, I., Igarashi, R., Fujihara, K., Takeda, Y., Ferreira, E. d'Ávila, Mon, K.L., Kodama, S., Mori, Y., Kadowaki, T., Honda, R., Arase, Y. and Sone, H. Cross-sectional and Longitudinal Associations Between Family History of Type 2 Diabetes Mellitus, Hypertension, and Dyslipidemia and Their Prevalence and Incidence: Toranomon Hospital Health Management Center Study (TOPICS24). Mayo Clinic Proceedings. (2025), [online] doi:https://doi.org/10.1016/j.mayocp.2024.10.020.

Grundy, S.M., Stone, N.J., Bailey, A.L., Beam, C., Birtcher, K.K., Blumenthal, R.S., Braun, L.T., de Ferranti, S., Faiella-Tommasino, J., Forman, D.E., Goldberg, R., Heidenreich, P.A., Hlatky, M.A., Jones, D.W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C.E., Orringer, C.E., Peralta, C.A. and Saseen, J.J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25). (2019), doi:https://doi.org/10.1161/cir.0000000000000624.

Sniderman, A.D.. ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease. Clinical Chemistry. (2021), doi:https://doi.org/10.1093/clinchem/hvab140.

Tran, C., Vo, V., Taylor, P., Koehn, D.A., Virani, S.S. and Dixon, D.L. Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center. Journal of clinical lipidology, 16(4), (2022), pp.491–497. doi:https://doi.org/10.1016/j.jacl.2022.05.003.

Chait, A., Eckel, R.H., Vráblík, M. and Zambón, A. Lipid-lowering in diabetes: An update. Atherosclerosis, 394, (2023), pp.117313–117313. doi:https://doi.org/10.1016/j.atherosclerosis.2023.117313.

O’Toole, T., Kelsey, M.D., Shah, N.P., McGarrah, R.W. and Pagidipati, N.J.. Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs. Current Cardiology Reports, 24(10), (2022), pp.1397–1406. doi:https://doi.org/10.1007/s11886-022-01760-y.

Jain, M., Sawant, R., Panchal, H., S, A., Jena, A., Gupta, R., Kumar, K., Jambunathan, R., Modi, S., Mullasari, A., Sinha, N., Shetty, K. and Kawatra, P. Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- A retrospective real-world study LDL-C control in ACS. International Journal of Cardiology Cardiovascular Risk and Prevention, [online] 19, (2023), p.200210. doi:https://doi.org/10.1016/j.ijcrp.2023.200210.

Laakso, M. and Lilian Fernandes Silva. Statins and risk of type 2 diabetes: Mechanism and clinical implications. Frontiers in Endocrinology, (2023), [online] 14(1239335). doi:https://doi.org/10.3389/fendo.2023.1239335.

Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B.G., Bruckert, E., De Backer, G., Krauss, R.M., Laufs, U., Santos, R.D., Hegele, R.A., Hovingh, G.K., Leiter, L.A., Mach, F. and März, W. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36(17), (2015), pp.1012–1022. doi:https://doi.org/10.1093/eurheartj/ehv043.

Martirossian, A.N. and Goldberg, A.C. Management of patients with statin intolerance. Best Practice & Research Clinical Endocrinology & Metabolism, 37(3), (2022), p.101714. doi:https://doi.org/10.1016/j.beem.2022.101714.